SUMMARY Prostaglandins have been shown in animal laboratory studies to be capable of protecting the gastrointestinal tract against injury by exogenous agents. This study was conducted to determine if prostaglandin E2 (PGE2), which is native to the human gastric mucosa, could influence the increase in faecal blood loss associated with the ingestion of aspirin (ASA). A randomised doubleblind study was performed on 27 healthy men. Faecal blood loss was measured by the 51Cr labelled red cell technique. ASA (600 mg four times daily) caused a significant increase in faecal blood loss. PGE2 (1 mg four times daily) had no effect on faecal blood loss when administered alone. When given in addition to ASA it resulted in a faecal blood loss not significantly different from control. No significant alteration in intestinal transit occurred. It is concluded that PGE2 protects man from the gastrointestinal injury associated with ASA.
Prostaglandin E2 (PGE2) occurs naturally in human gastric mucosa,' but its physiological role is not clear. Inhibition of acid secretion2 and stimulation of mucus production3 4 and nonparietal cell secretion>7 have been documented. In animal experiments a 'cytoprotective' property has been described8 by which gastric erosions induced by a variety of exogenous agents can be prevented by prostaglandin analogues incapable of acid inhibition or by doses of PGE2 below the threshhold for acid inhibition.9 There is evidence in man that aspirininduced changes in gastric transmucosal potential difference can be prevented by PGE2.10 In clinical practice, aspirin may cause significant gastrointestinal bleeding"1 probably due to injury to the gastric mucosa.12 Most individuals on large doses of aspirin lose an extra few millilitres of blood each day in their faeces.13 14 This study was conducted to determine if oral PGE2 could prevent this increased faecal blood loss associated with the ingestion of aspirin. consent and the study was approved by the ethics committee of the University of British Columbia. Initial screening comprised a full medical history, physical examination, and standard laboratory studies. Subjects were excluded who were known to be taking steroids within the past six months, or aspirin or any other analgesics within the previous two weeks. Individuals with a history of ulcer disease or haemorrhoids were also excluded.
The subjects were randomly allocated to one of four groups using a table of random numbers (Table 1 ). All drugs were administered before meals and at bedtime. PGE2 was started 24 hours before the ASA and individual doses were taken 30 minutes before ASA. PGE2 was supplied as 1.0 mg in 5 ml 10% ethanol, which was diluted by the subject in 100 ml tap water. ASA was supplied as nonbufferred 300 mg tablets. Drug administration Trinder's method which gives a low background value for serum which contains no salicylate. The initial laboratory studies were repeated at the conclusion of the study.
Results
Four of the original subjects were not included in the analysis of the data: two lost their drug supply and two had baseline faecal blood content greater than 5 ml/day. The only side-effect recorded (Table 1) .
Faecal blood loss in ml/day in the four treatment groups is given in Table 2 and shown in the Figure. content in the stool occurred one day after aspirin administration was stopped-that is, it coincided with the second day of aspirin treatment after intestinal transit time was allowed for. Mean blood loss in the groups who received aspirin plus PGE2 or PGE2 plus placebo was not significantly different from that in the double placebo group. Mean blood loss in the group receiving aspirin plus PGE2 was significantly less (p< 0.05) than in the group receiving aspirin plus placebo.
No changes were detected in the laboratory values at the completion of the study.
Discussion
The results of this study confirmed our preliminary data"8 and indicate that oral PGE2 will protect the human stomach against the damage normally caused by standard therapeutic doses of aspirin. Preliminary data also show that the damage done by indomethacin in arthritic patients can be similarly prevented. 19 The concept that prostaglandins, which are synthesised by the gastric mucosa, play a role in protecting the gastric mucosa against injury is attractive. A 'cytoprotective' action of the prostaglandins has been known for some years, but it has only recently been recognised that this action is unrelated to inhibition of acid secretion. Thus the precise mechanism of this protective action remains unclear. Prostaglandins have several additional actions on the gastric mucosa all of which are potentially beneficial. Mucus secretion is stimulated,3 4 bicarbonate secretion is stimulated,5-7 19 and blood flow is increased.21-23 Although the prostaglandins have no effect on the normal gastric mucosal barrier,24 there is evidence that prostaglandin can prevent10 and reverse26 damage to the gastric mucosal barrier. The results of this investigation do not permit deductions about the mechanism of action of prostaglandins but clearly confirm that the protection afforded is unrelated to acid inhibition as oral PGE2 has no effect on human gastric acid secretion.27
Aspirin, indomethacin, and the other more recently introduced non-steroid anti-inflammatory analgesics all inhibit prostaglandin synthesis and all cause damage to the gastric mucosa. The proof that these agents damage the mucosa as the direct result of the inhibition of prostaglandin synthetase is still lacking. The indirect evidence is accumulating and our results add human data to that obtained from animal studies.
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